Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

An avatar for precision cancer therapy

Screening patient-derived tumor cell cultures against a drug library is a promising adjunct to clinical decision-making.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1


  1. O'Brien, S.G. et al. N. Engl. J. Med. 348, 994–1004 (2003).

    CAS  Article  Google Scholar 

  2. Slamon, D.J. et al. N. Engl. J. Med. 344, 783–792 (2001).

    CAS  Article  Google Scholar 

  3. Soria, J.C. et al. N. Engl. J. Med. 378, 113–125 (2018).

    CAS  Article  Google Scholar 

  4. Tsimberidou, A.M. et al. JCO Precis. Oncol. 2017, (2017).

  5. Wheler, J.J. et al. Cancer Res. 76, 3690–3701 (2016).

    CAS  Article  Google Scholar 

  6. Lee, J.-K. et al. Nat. Genet. 50, 1399–1411 (2018).

    CAS  Article  Google Scholar 

  7. Vlachogiannis, G. et al. Science 359, 920–926 (2018).

    CAS  Article  Google Scholar 

  8. Gao, H. et al. Nat. Med. 21, 1318–1325 (2015).

    CAS  Article  Google Scholar 

  9. Kodack, D.P. et al. Cell Rep. 21, 3298–3309 (2017).

    CAS  Article  Google Scholar 

  10. Jacobsen, E., Shanmugam, V. & Jagannathan, J. N. Engl. J. Med. 377, 2398–2399 (2017).

    Article  Google Scholar 

  11. Janku, F. et al. Cell Rep. 6, 377–387 (2014).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Razelle Kurzrock.

Ethics declarations

Competing interests

R.K. receives research funding from Genentech, Incyte, Merck, Serono, Pfizer, Sequenom, Foundation Medicine, Konica Minolta, Grifols and Guardant, as well as receiving consultant fees from Loxo, X Biotech, NeoMed and Actuate Therapeutics, receiving speaker fees from Roche, and holding an ownership interest in IDbyDNA and Curematch Inc.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kato, S., Kurzrock, R. An avatar for precision cancer therapy. Nat Biotechnol 36, 1053–1055 (2018).

Download citation

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer